Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition

Authors
Category Primary study
ConferenceBlood
Year 2024
This article has no abstract
Epistemonikos ID: cc387d1417d8b54374ff304f737cf07c0ac2c17a
First added on: Apr 29, 2026